Slowing Progression in CKD: DAPA CKD and Beyond

Clin J Am Soc Nephrol. 2021 Jul;16(7):1117-1119. doi: 10.2215/CJN.20211220. Epub 2021 Mar 10.
No abstract available

Keywords: CKD; MRA chronic kidney disease; SGLT2i; delay; evidence; progression.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Benzhydryl Compounds / therapeutic use*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetic Nephropathies / drug therapy
  • Disease Progression
  • Drug Therapy, Combination
  • Glucosides / therapeutic use*
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / physiopathology
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzhydryl Compounds
  • Glucosides
  • Mineralocorticoid Receptor Antagonists
  • Sodium-Glucose Transporter 2 Inhibitors
  • dapagliflozin